Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESR-114
- Development stage
- Phase 2
- Lead developer
- Escalier Biosciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ESR-114 is a selective, potent small molecule inhibitor of retinoic acid-related orphan nuclear receptor gamma t (RORγt), also known as nuclear receptor subfamily 1 group F member 3. It is being developed as a topical gel formulation designed to target its pharmacological activity to the skin with minimal systemic absorption. The mechanism of action involves antagonism of RORγt, which reduces production of the inflammatory cytokine IL-17—a key driver in psoriasis and other autoimmune disorders. The drug is primarily being investigated for the treatment of plaque psoriasis, with clinical trials reaching Phase 1/2a status in patients with mild-to-moderate disease[1][2][3][4].
- Other names
- ESR 114ESR114ESR-114
02
Targets
RORγtRORC (Retinoic acid receptor-related orphan receptor gamma)
Beyond the preview
Go deeper on ESR-114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESR-114.